There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Puma Biotechnology (PBYI – Research Report) and Selecta Biosciences (SELB – Research Report) with bullish sentiments.
Puma Biotechnology (PBYI)
H.C. Wainwright analyst Edward White reiterated a Buy rating on Puma Biotechnology yesterday and set a price target of $12.00. The company’s shares closed last Monday at $2.39, close to its 52-week low of $1.60.
According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Puma Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.
Selecta Biosciences (SELB)
In a report released yesterday, Joseph Schwartz from SVB Securities initiated coverage with a Buy rating on Selecta Biosciences and a price target of $7.00. The company’s shares closed last Monday at $1.00, close to its 52-week low of $0.65.
According to TipRanks.com, Schwartz ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Selecta Biosciences is a Strong Buy with an average price target of $7.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PBYI: